ArticleImmune network2025
Strong Immune Privileges of MSC and Other Nes-GFP
Article in Immune network, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nitric Oxide in the Intestinal Stem Cell Niche: A Spatial Model of Nitrosative Stress and Clonal Evolution in Colitis-Associated Colorectal Cancer.Digestive diseases and sciences · 2026Review
- Cell-based therapies of autoimmune diseases in the context of artificial intelligence development.Clinical and experimental medicine · 2026Review
- Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8BMC medicine · 2026Article
- Comparative gene expression analysis of nestin-expressing hair follicle-derived cells.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune privileges (IPs) have been demonstrated for several types of quiescent stem cells (SCs) in adult mammalian organisms. Cancer SCs (CSCs) also manifest IPs, which is one of the main concerns in cancer therapy. To elucidate the strength of non-pathological SCs IPs, we implanted bone marrow (BM) of transgenic N-GFPCF1 mice under the renal capsule of non-transgenic mice immunized with enhanced green fluorescent protein (GFP). We show that Nes-GFP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.